...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Zenith AGM Corporation Update Slides and Webcast

"Hopefully the Phase 2a mCRPC trialĀ  results are good, but Zenith has yet been able to garnish a large BP partner."

Yeah, I guess partnering with tiny Pfizer on the ongoing triple negative breast cancer trial with ZEN-3694 and PARP inhibitor doesn't count.

BDAZ

Share
New Message
Please login to post a reply